Fig. 1From: Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspectiveModel schematic. AC, anthracycline; ALVD, asymptomatic left ventricular disease; CHF, congestive heart failure; XRT, chest irradiationBack to article page